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FEMALE GENDER IS PROTECTIVE FOR OUTCOMES AFTER PRIMARY
TOTAL KNEE ARTHROPLASTY: A RISK-ADJUSTED ANALYSIS
J.A. Singh 1, C. Kwoh 2, D. Richardson 3, W. Chen 4, S. Ibrahim 5. 1Univ. of
Alabama and Birmingham VA Med. Ctr., Birmingham, AL, USA; 2Univ. of
Pittsburgh and Pittsburgh VA Med. Ctr., Pittsburgh, PA, USA; 3Univ. of
Pennsylvania and Philadelphia VA Med. Ctr., Philadelphia, PA, USA; 4Univ.
of Pennsylvania and Philadelphia VA Med. Ctr., Philadelphia, AL, USA;
5Univ. of Pennsylvania and Philadelphia VA Med. Ctr., philadelphia, PA, USA
Purpose: Osteoarthritis is more prevalent in women than men. Joint
replacement is an effective treatment option for end-stage knee OA and its
utilization is increasing rapidly. There are, however, limited data on gender
differences in surgical outcomes after total joint arthroplasty. We sought to
examine gender differences in overall mortality, major complications,
revision rates and re-admission rates after primary total knee
arthroplasty..
Methods: The sample consisted of all primary knee total joint arthro-
plasties performed in the State of Pennsylvania during the ﬁscal year
2002. Primary knee arthroplasty was identiﬁed using the International
Classiﬁcation of Diseases, Ninth revision, Clinical Modiﬁcation (ICD-9-
CM) code 81.54 in the Pennsylvania Health Care Cost Containment
Council (PHC4) Database. We excluded patients with revision knee
arthroplasty or with hip joint related procedures during index hospital-
ization. PHC4 includes demographic data from all patient discharges from
170 non-governmental (i.e. non-Veterans Administration) acute care
hospitals in the State of Pennsylvania. We used ICD-9 codes to identify
major complications such as venous thromboembolism (VTE), myocardial
infarction (MI), prosthetic device malfunction, surgical wound infection
and revision knee arthroplasty (ICD-9 codes, 81.55, 0080, 0081, 0082,
0083, and 0084). We examined the associations between gender and all-
cause mortality, major surgical complications. risk of surgical revision at
1-year and at 5-years after index arthroplasty. We adjusted for age, race
or ethnicity, hospital teaching status (teaching or non-teaching), insur-
ance status (none or unknown, Medicaid, Medicare/ government, or
private), hospital procedure volume (0-100 and >100), and length of
hospital stay and the 3M[[Unsupported Character - ]] All Patient
Reﬁned-Diagnosis Related Group Risk of Mortality (APR-ROM) score,
a validated surgical risk score.
Results: In sample consisting of 19,312 primary total knee arthroplasties,
there were 47 deaths (0.2%) at 30 days and 232 (1.2%) at one year. Within
30 days of index TKA, 1076 (5.8%) had major complications. Table 1
shows unadjusted rates of major complications. Compared to women,
men had higher adjusted odds of one-year mortality (Odds Ratio (OR),
1.50; 95% CI, [1.22-1.86]), wound infections (1.23 [1.01-1.49]) and 30-day
readmission (1.44 [0.80-2.57]) after primary TKA. Men also had signiﬁ-
cantly higher risk of revision arthroplasty of the primary TKA at 1-year
(Hazard Ratio(HR), 1.60; 95% CI¼ 1.27-2.03) and 5-years (1.21; 95% CI¼
1.08-1.37). There were no statistically signiﬁcant gender differences in
the rates of short-term complications (i.e., venous thromboembolism,Table 1
Unadjusted rates (n (%)) of surgical outcomes of TKA comparing women to men
Total (n¼19,312)
30-day Complications
Overall complications 1076 (5.57%)
Myocardial Infarction (MI) 92 (0.47%)
Venous thromboembolism (VTE) 510 (2.64%)
Wound infection 461 (2.38%)
Prosthesis failure or device 60 (0.31%)
Readmission and Mortality
30-day readmission 1121 (5.80%)
30 days mortality 47 (0.24%)
1 year mortality 232 (1.20%)
Revision Rates
1-year revision 298 (1.56 %)
5-year revision 1012 (5.76%)myocardial infarction, prosthetic device malfunction or 30-day
mortality).
Conclusion: In a large regional sample of patients who underwent
primary total knee arthroplasty, men had higher rates of adverse surgical
outcomes including higher short- and intermediate-term revision rates
compared to women.
588
EFFECTIVENESS OF HYALURONIC ACID INTRA-ARTICULAR INJECTION
FOR PATIENTS WITH KNEE OSTEOARTHRITIS
Y. Kusayama, Y. Akamatsu, K. Kumagai, Y. Fujiwara, T. Saitou. Yokohama
City Univ., Sch. of Med., Kanagawa prefecture Yokohama city, Japan
Purpose: Hyaluronic acid (HA) intra-articular injection for the treatment
of patients with knee osteoarthritis (OA) was ﬁrstly manufactured in 1987,
and has been routinely used in Japan. However, there was only a small
amount of evidence. We have performed ﬁve weekly HA injections
according to the insurance policy. The purpose of this study was to
investigate the change of the nature of synovial ﬂuid (SF) and clinical
symptoms before and after ﬁve weekly HA injections.
Method: Fifteen patients (17 knees) with symptomatic knee OA were
enrolled between January 2010 and July 2011. We conducted 5 weekly
intra-articular injections (Artz, Seikagaku Corporation, Tokyo, Japan) after
drainage of SF in every cases. The arthrocentesis was performed through
lateral mid patellar portal using a 21-gauge needle and syringe, while
avoiding the contamination of blood. We checked total volume of SF
drainage before each HA injection. Also, we measured molecular weight of
hyaluronic acid (HA),chondroitin 4-sulfate (C4S), chondroitin 6-sulfate
(C6S) and keratan sulfate (KS) before ﬁrst and ﬁfth time. We excluded the
case if the SF could not be extracted. We decided not to administer aspirin
and nonsteroidal anti-inﬂammatory drugs six weeks before injections and
during injections. The range of motions (ROM) were measured and clinical
symptoms were using American Knee Society (AKS) knee and function
scores. All knees were classiﬁed using the Kellgren-Lawrence grades (KL
grade), and the femorotibial angle (FTA) was measured on the radiogram.
Result: Four dry knees were excluded before the ﬁrst injection. Thirteen
knees (right 8 and left 5 knees) were examined. Mean age was 63  10.7
years old, andmean bodymass index was 22.12.5 kg/m2. KL grades were
grade 2 in 9 knees and grades 3-4 in 4 knees. Mean FTA was 178.5  3.5.
We didn't have complications and side effects. Mean volume of SF, which
was 11.8ml before ﬁrst injection, and 6.2 m before ﬁfth injection, signiﬁ-
cantly decreased after HA injections (p < 0.05). Mean AKS knee score,
which was 61 points before ﬁrst injection and 77 points before ﬁfth
injection, signiﬁcantly improved after HA injections (p < 0.0001). Mean
ROM, which was 134 10 before ﬁrst injection and 140.8 7 before ﬁfth
injection, signiﬁcantly improved after HA injections (p < 0.009). Mean
molecular weight of HA, C4S, C6S and KS, which were 1.4 mg/ml, 15.1
nmol/m 50.7 nmol/ml and 4.3 micro g/ml, respectively, before ﬁrst injec-
tion, changed to 1.7 mg/ml,12.7 nmol/ml, 41.9 nmol/ml and 3.7 micro g/ml,
respectively, before ﬁfth injection.Female (n¼12,557) Male (n¼6,755) P-value
663 (5.27%) 413 (6.11%) 0.016
52 (0.41%) 40 (0.59%) 0.087
323 (2.57%) 187 (2.76%) 0.418
277 (2.20%) 184 (2.72%) 0.025
36 (0.28%) 24 (0.35%) 0.414
674 (5.36%) 447 (6.61%) 0.0004
25 (0.19%) 22 (0.32%) 0.089
125 (0.99%) 22 (1.58%) 0.0003
162 (1.30%) 136 (2.04%) 0.0001
627 (5.42 %) 385 (6.42%) 0.007
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S295ĂConclusion: The effectiveness of HA injections for the treatment of
patients with knee OA remains unclear. Some researchers reported that
the volume of SF and the molecular weight of C4S, C6S and KS decreased,
and themolecular weight of HA increased after ﬁveweekly injections. Also
they reported that clinical symptoms improved after HA injections. Our
results showed that the ROM improved with the decrease of SF after ﬁve
weekly injection. The destruction of proteoglycan in articular cartilage
resulted in the decrease of the molecular weight of C4S, C6S, and KS.
However, our results showed that molecular weight of HA, C4S, C6S and KS
before HA injection did not change after HA injection. A possible reason of
the difference between previous and this studies might be related with the
small number of this study. In summary, our study showed that clinical
symptoms and ROM improved with the decrease of effusion, although the
destructive products of cartilage did not change after ﬁve weekly HA
injections. In future, we should enrolled many patients with knee OA and
investigate the relationship between the proceeding of knee OA and the
destructive products of cartilage.
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DESIGN RATIONALE AND EARLY CLINICAL / SURGICAL OBSERVATIONS
WITH A TISSUE SPARING STEM FOR THA IN OSTEOARTHRITIS
T. McTighe 1, D. Brazil 2. The TSI Study Group1 Joint Implant Surgery and
Res. Fndn., Chagrin Falls, OH, USA; 2 Joint Implant Surgery and Res. Fndn.,
Sydney, Australia
Abstract: Architectural changes occurring in the proximal femur after
THA continues to be a problem. Proximal stress shielding occurs
regardless of ﬁxation method. The resultant bone loss can lead to implant
loosening and or breakage of the implant. We are seeing younger
patients with higher levels of physical activity as compared to just
a decade ago. A tissue sparing total hip stem provides for less tissue
damage, a quicker rehab and leaves behind more infrastructure in case of
future revision surgery.
Introduction: Patients today demand more out of the hip recon-
struction and their increase activity places a higher demand on the
implant. A number of the current short stems introduced into the
market are no more than standard stems cut short. There is concern
with the increase in younger and more active patients that these
modiﬁed short stems be adequate to resist the increased biome-
chanical loads placed on them?
The purpose of this paper is to review a new novel neck sparing total hip
stem and the method by which this stem achieves implant/bone stability,
surgical technique required, and observations as to early clinical outcomes.
Material: There have been 750 stems implanted with this novel neck
sparing stem design since April 2010 with 600 from the surgical team
(seven) posted for review. . All seven were part of the initial surgical team
to aid in designing and ﬁne-tuning of surgical instruments. Typical patient
proﬁle showed two-thirds being female with an age range overall between
17 to early 90s. 90%were treated for OA. This stem has been used in all Dorr
bone classiﬁcations (A, B, &C). Two surgical approaches were utilized the
single anterior incision and standard posterior incision.
Results: Anterior Approach Dislocations ¼ 2 Stem Revisions ¼ 3 Aseptic
Loosening ¼ 1 Superﬁcial Infection ¼ 2 Septic Loosening ¼ 0 Leg / Length
Discrepancy +/- 7 mm ¼ 9 / 0.3% Occult fracture distal end of stem ¼ 1
Calcar Fractures wired ¼ 2 Calcar Fractures not wired ¼ 3 Hip pain ¼ 1
Subsidence > 5mm ¼ 3 Intra-op femoral perforation ¼ 3 Intra-op calcar
fractures resulting in stem bailout ¼ 0 Posterior Approach Dislocations¼ 2
Stem Revisions ¼ 1 Aseptic Loosening ¼ 0 Septic Loosening ¼ 1 Superﬁcial
Infection¼ 0 Leg / length Discrepancy +/- 7 mm¼ 3 / .013% Fractures distal
¼ 0 Calcar Cracks wired ¼ 0 Calcar Cracks not wired ¼ 1 Hip pain ¼ 1(process of being worked up/ potential spine problem) Subsidence > 5mm
¼ 0 Intra-op calcar fractures resulting in stem bailout ¼ 2
Discussion: There is a short learning curve for the surgeon (2-3 cases)
and an easy transition for the O.R. surgical team with only one pan of
instruments. Six of the seven surgeons feel that these patients with this
short curved neck-sparing stem have gotten back to full weight bearing
and a full active life style quicker than their conventional cementless
THA. One surgeon gauges them as equivalent to his conventional stems.
All feel that there is less blood loss and operative times have been
reduced.
The few explants have proven to be easily converted to a primary stem for
revisions. Two intra-operative calcar fractures resulted in a bail out to
a conventional primary cementless stem. The modular neck has proven to
be beneﬁcial in a couple of cases for access to the socket in revision situ-
ations. The modularity of the neck also helps reducing risk of mechanical
impingement.
There have been minor incidence of over lengthening the leg (11) greater
than 7 mm however; none have had to be revised.
We are encouragedwith our initial clinical / surgical observations (patients
are happy) and believe the potential and real beneﬁts warrant not only
further evaluation but expanded evaluation of this tissue conserving
approach to THA.
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INTRA-ARTICULAR GROWTH HORMONE INJECTIONS REGROW
CARTILAGE, INCREASE MOTION AND REDUCE PAIN IN 93 PER CENT.
OF ARTHRITIC ANKLES.
A.R. Dunn. Mt. Sinai Med. Ctr., Miami Beach Florida, FL, USA
Purpose: Purpose: The author uses intra-articular growth hormone(iagh)
injections as a treatment for osteoarthritis(OA) of the ankle. Results of this
treatment were ﬁrst observed in the author's studies of cartilage healing
following intra-articular growth hormone(IAGH) injections in surgically
debrided knees in mature rabbits. Iagh causes Pre-natal Developmental
Healing(PDH) of cartilage which grows fetal cartilage by recapitulation of
the cascades of development. PDH involves no inﬂammation and produces
no scar tissue. The method was translated to the iagh treatment of 14
patients with advanced OA of the ankle. Age ranged from 37 to 76 years.
There were 10 males and 4 females followed 2 to 4 years post treatment.
Iagh treatment has no side effects, complications, infections, or deaths.
